blood and urine

PreclinicalBiologic

CCentre Oscar Lambret

blood and urine is one of 6 biologic programs targeting Angiosarcoma. It is currently in Preclinical.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[3][1]

Indication

AngiosarcomaActive, not recruiting

AngiosarcomaPreclinical

Active, not recruiting

Competition

Competitive Landscape

5 competitors in Angiosarcoma

#DrugCompanyPhaseTrials

Halaven

Eisai

Approved

1 2

Adriamycin

Taxol

6 4

Keytruda

Merck & Co.

Phase 2

3 5

Vusolimogene Oderparepvec

YYana Najjar

Phase 2

1 6

blood and urine

CCentre Oscar Lambret

Preclinical

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Clinical

Trials by Indication[1]

Angiosarcoma1 trial

Identification, Molecular Epidemiology Angiosarcoma of the Liver France

Unknown status·CCentre Oscar Lambret·N/A·NCT01786889·9 enrolled

Sources

References

[1]
ClinicalTrials.gov — 1 trial record for blood and urine. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — blood and urine compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for blood and urine. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — Centre Oscar Lambret company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Biologic[2]
Highest Phase: Preclinical[1]
Company: CCentre Oscar Lambret

blood and urine

Status by Indication[3][1]

Competitive Landscape

Trials by Indication[1]

Angiosarcoma1 trial

References

Drug Info

Quick Facts

Related News